BSFAF (BSF Enterprise) ROIC %: -24.83% (As of Sep. 2025)


What is BSF Enterprise ROIC %?

BSF Enterprise BSFAF ROIC % is -24.83% as of Sep. 2025. The stock has 3 warning signs investors should review.

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. BSF Enterprise's annualized return on invested capital (ROIC %) for the quarter that ended in Sep. 2025 was -24.83%.

As of today (2026-06-27), BSF Enterprise's WACC % is 12.93%. BSF Enterprise's ROIC % is -41.02% (calculated using TTM income statement data). BSF Enterprise earns returns that do not match up to its cost of capital. It will destroy value as it grows.


BSF Enterprise  (OTCPK:BSFAF) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, BSF Enterprise's WACC % is 12.93%. BSF Enterprise's ROIC % is -41.02% (calculated using TTM income statement data). BSF Enterprise earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


BSF Enterprise ROIC % Related Terms


BSF Enterprise ROIC % Historical Data

* Premium members only.

The historical data trend for BSF Enterprise's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BSF Enterprise ROIC % Chart

BSF Enterprise Annual Data
Trend Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
ROIC %
Get a 7-Day Free Trial -219.18 -52.06 -54.09 -60.33 -40.90

BSF Enterprise Semi-Annual Data
Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
ROIC % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -39.22 -60.57 -58.04 -57.23 -24.83

BSFAF vs VRTX, REGN, ALNY: ROIC % Comparison

For the Biotechnology subindustry, BSF Enterprise's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BSF Enterprise ROIC % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BSF Enterprise's ROIC % distribution charts can be found below:

* The bar in red indicates where BSF Enterprise's ROIC % falls into.



BSF Enterprise ROIC % Calculation

BSF Enterprise's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Sep. 2025 is calculated as:

ROIC % (A: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Sep. 2024 ) + Invested Capital (A: Sep. 2025 ))/ count )
=-1.641 * ( 1 - 8.45% )/( (3.714 + 3.632)/ 2 )
=-1.5023355/3.673
=-40.90 %

where

BSF Enterprise's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Sep. 2025 is calculated as:

ROIC % (Q: Sep. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2025 ) + Invested Capital (Q: Sep. 2025 ))/ count )
=-1.144 * ( 1 - 23.6% )/( (3.408 + 3.632)/ 2 )
=-0.874016/3.52
=-24.83 %

where

Note: The Operating Income data used here is two times the semi-annual (Sep. 2025) data. The tax rate is limited to between 0% and 100%.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROIC % →
What does a ROIC % of -24.83% mean?
BSF Enterprise (BSFAF) has a ROIC % of -24.83% as of Sep. 2025. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BSF Enterprise and its competitors.
Is BSF Enterprise's ROIC % too high?
BSF Enterprise's current ROIC % is -24.83%.
How does BSF Enterprise's ROIC % compare to VRTX and REGN?
BSF Enterprise's ROIC % of -24.83% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROIC % for a Biotechnology company?
A good ROIC % depends on the Biotechnology industry context. However, ROIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROIC % mean?
A high ROIC % can signal that a stock is expensive relative to its fundamentals. Return on invested capital is the ratio of current-period net income to average two-period invested capital. View historical data on BSF Enterprise and its competitors. BSF Enterprise's current ROIC % is -24.83%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BSF Enterprise stock overvalued right now?
BSF Enterprise (BSFAF) has a current ROIC % of -24.83%. The current ROIC % is -24.83%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROIC % calculated?
ROIC % is calculated from a company's financial statements. For BSF Enterprise (BSFAF), the current ROIC % is -24.83% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

BSF Enterprise Business Description

Other Exchanges BSFA:UK
Address 2 Portman Street, London, GBR, W1H 6DU
BSF Enterprise PLC is a United Kingdom-based biotech company. The Company is focused on developing biotechnological solutions using cell-based tissue engineering to help generate cultured meat, lab-grown leather, as well as human corneas, collagen growth and skin substitutes. The Company operates through its wholly owned subsidiary, 3D Bio-Tissues Limited (3DBT), which is a clinical and cellular agriculture company engaged in producing human corneas that could help restore vision to millions of people.